NEW DRUGS: RUXOLITINIB
Expanding the AD Treatment Armamentarium With Lawrence F. Eichenfield, MD New topical nonsteroidal improves signs and symptoms of AD The FDA approval of ruxolitinib 1.5% cream (Opzelura, Incyte) for the treatment of atopic dermatitis (AD) provides dermatologists with a new nonsteroidal option offering both anti-inflammatory and anti-pruritic activity. “Ruxolitinib is the first janus kinase (JAK) […]